期刊文献+

非布司他治疗维持血液透析痛风伴高尿酸血症的临床效果 被引量:12

The Clinical Effect of Febuxostat Therapy on Hemodialysis with Gout and Hyperuricemia
下载PDF
导出
摘要 目的探讨非布司他治疗维持血液透析痛风伴高尿酸血症的临床效果。方法选取2015年4月~2016年9月我院收治维持血液透析痛风患者共150例,将其随机分为3组,每组50例。治疗组1给予非布司他40mg,l次/d,疗程为20w;治疗组2予非布司他80mg,l次/d,疗程为20w;对照组给予别嘌呤醇100mg,3次/d治疗,疗程为20w。对患者治疗前、治疗8w以及20w后3组的血尿酸水平和治疗前后肝肾功能变化情况进行记录与分析。结果 3组患者在治疗后血尿酸与治疗前相比均有下降较治疗前均有下降,差异具有统计学意义(P<0.05)。治疗组1、治疗组2与对照组相比,患者的血尿酸下降更加显著(P<0.05)。结论非布司他、别嘌呤醇在维持血液透析痛风伴高尿酸血症患者临床治疗中具有较好的临床治疗效果,非布司他降尿酸的耐受性良好,且安全性较好,可在临床推广应用。
出处 《现代诊断与治疗》 CAS 2017年第11期1990-1991,共2页 Modern Diagnosis and Treatment
  • 相关文献

参考文献7

二级参考文献97

  • 1关宝生,白雪,王艳秋,尹相林,李若男,周宪君,徐辉,杜文彦,邱洪斌.痛风/高尿酸血症患者生活习惯的危险因素[J].中国老年学杂志,2014,34(2):455-457. 被引量:62
  • 2朱深银,周远大,杜冠华.防治痛风药物的研究进展[J].医药导报,2006,25(8):803-806. 被引量:31
  • 3Takano Y,Hase-Aoki K,Horiuchi H,et al.Selectivity of febuxostat,a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.Life Sci,2005,76(16):1835-1847.
  • 4Bruce SP.Febuxostat:a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.Ann Pharmacother,2006,40(12):2187-2194.
  • 5Mayer MD,Khosravan R,Vernillet L,et al.Pharmacokinetics and pharmacodynamics of febuxostat,a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.Am J Ther,2005,12(1):22-34.
  • 6Khosravan R,Grabowski BA,Wu JT,et al.Pharmacokinetics,pharmacodynamics and safety of febuxostat,a non-purine selective inhibitor of xanthine oxidase,in a dose escalation study in healthy subjects.Clin Pharmacokinet,2006,45(8):821-841.
  • 7Khosravan R,Grabowski BA,Mayer MD,et al.The effect of mild and moderate hepatic impairment on pharmacokinetics,pharmacodynamics,and safety of febuxostat,a novel nonpurine selective inhibitor of xanthine oxidase.J Clin Pharmacol,2006,46(1):88-102.
  • 8Becker MA,Schumacher HR,Wortmann RL,et al.Febuxostat,a novel nonpurine selective inhibitor of xanthine oxidase:a twenty-eight-day,multicenter,phaseⅡ,randomized,double-blind,placebo-controlled,dose-response clinical trial examining safety and efficacy in patients with gout.Arthritis Rheum,2005,52(3):916-923.
  • 9Schumacher HR,Becker MA,Wortmann RL,et al.Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout:a 28-week,phase Ⅲ,randomized,double-blind,parallel-group trial.Arthritis Rheum,2008,59(11):1540-1548.
  • 10Becker MA,Schumacher HR,Wortmann RL,et al.Febuxostat compared with allopurinol in patients with hyperuricemia and gout.N Engl J Med,2005,353(23):2450-2461.

共引文献137

同被引文献72

引证文献12

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部